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Microchimerism is deﬁned as the presence of two genetically distinct cell populations in the same individual. It can arise from
several causes including the bidirectional transfer of cells between mother and fetus during pregnancy, twin-to-twin transfer in
utero, from organ transplantation, and blood transfusion. Recently, scientists have found male fetal cells from decades earlier
imbedded in tissues and organs of somewomenwith autoimmunediseases. The signiﬁcanceof these ﬁndings as they relate to real
or potential health implications in autoimmune diseases, graft-versus-host reactions, and transfusion complications is discussed
here.
1.Microchimerism
Microchimerism is deﬁned as the presence of low concen-
trations of two genetically distinct cell populations in the
same individual. It can arise from several causes including
the bidirectional transfer of cells between mother and fetus
during pregnancy, twin-to-twin transfer in utero,from organ
transplantation, and blood transfusion. Recently, there has
been increasing interest in fetomaternal microchimerism as
it relates to real or potential health implications in autoim-
mune diseases, graft-versus-host reactions, and transfusion
complications (see Figure 1).
The fetal and maternal cell exchange is common in
pregnancy. We now know that the placenta is not an
immunologically inert barrier, but rather, it allows the recip-
rocal transport of maternal and fetal cells in a state ofmutual
tolerance during gestation. To develop microchimerism, it is
not necessary to continue a pregnancy and deliver an infant.
Early terminations from surgical abortion can deliver up
to 500,000 nucleated fetal cells into a woman’s circulation
[1]. Fetal microchimerism in maternal blood and tissues is
typically identiﬁed using polymerase chain reaction (PCR)
to identify Y-chromosome DNA sequences in the mother.
Microchimerism does not require the fetus to be male, but
it is easier to distinguish the Y chromosome as a biomarker.
Interestingly, male microchimerism has been found in a ﬁfth
of women with no male births. This can occur in a number
of ways including early miscarriage of a male embryo, a
vanished male twin, male cell transfer from an older sibling
through thematernalcirculation toalaterpregnancy, ora yet
unexplored possibility, that of male DNA transferred to the
woman’s circulation from sexual intercourse [2]. Male fetal
cells appear to have increased antigenicity in females. During
pregnancy, a woman confronts an immunological challenge,
because the fetus carries paternal genes, some of which
are expressed on the cell surface and may provoke potent
allogeneic responses. Yet, in spite of these immunologic cell
diﬀerences, rejection of the fetus does not frequently occur
[3].
1.1. The Role of Human Leukocyte Antigens (HLA). The
major histocompatibility complex (MHC) is the body’s
antiviral spyware program that resides on chromosome 6.
The MHC contains genes that are involved in recognizing
selffromnonself andincludehumanleukocyteantigengenes
(HLA).TheHLAsystemcontainsover200genes,40ofwhich
are involved with encoding leukocyte antigens [4]. HLA
consists of two diﬀerent classes, each with distinct functions.
Class I antigens (A, B, and C) present antigens that invade
cells; Class II antigens (DR, DP, and DQ) present antigens,
so T-lymphocytes can determine if they should help B-cells
make more antibody to a particular antigen.2 ISRN Nursing
Figure 1: A Chimera.
The HLA genes tend to be inherited as a group, one from
the mother and one from the father. The proteins encoded
by HLA are the proteins on the outer part of body cells
that are unique to a person. The HLA system is involved
with such diverse clinical conditions as organ rejection in
transplantation, death from infection in immunodeﬁciency,
hepatic cirrhosis caused from iron overload, and autoim-
munediseases[4].Thisisthereasonwhy donorsarematched
at major histocompatibility alleles (HLA-A,B,DR) in stem-
cell transplantations. Yet, minor histocompatibility antigens
such asH-Yantigen may playa bitmore havocin disease and
transplant rejection than was previously thought [5].
1.2. The Y Chromosome and the H-Y Antigen. In the
genetically male fetus, the Y chromosome contains a gene
that codes for a protein called H-Y antigen. When H-Y
antigen secretion begins, the primordial gonads become
testes. Without a Y chromosome, there is no H-Y protein,
and the primordial gonads become ovaries. H-Y is a minor
histocompatibility antigen present on all male cells that is
widely conserved in evolution [6]. It has been detected in
cells from every mammalian species tested. The gene for
the H-Y antigen is located on the short arm of the Y
chromosome. Males develop tolerance to these self antigens,
but female T cells are capable of recognizing peptides
derived from H-Y proteins following transplantation. Sex-
mismatched transplantations can result in major activation
of the immune system even in the face of HLA-identical
allografts. The risk of rejection is far greater with male solid
organ grafts into female recipients [7].
Although the exchange of fetal maternal cells is common
with all pregnancies, there appears to be increased levels of
immune complexes in the serum of newborn males than
in newborn females [6]. This may occur because women
who have delivered male oﬀspring can produce antibodies to
H-Y proteins. In subsequent pregnancies with males, those
antibodies can cross the placenta and react with circulating
H-Yantigenandformimmunecomplexes.Oneofthefactors
that increase graft-versus-host disease in allogeneic stem-
cell transplantation is the use of multiparous females as
donors. It has been reported that male fetal progenitor cells
have been detected as long as 27 years postpartum [8]. This
phenomenon, however, is not evident in all women nor is it
evident in all male oﬀspring.
Findings from a London hospital-based study revealed
that women who developed cytotoxic antibodies during
their ﬁrst pregnancy had signiﬁcantly more male infants,
suggesting that the male fetus is more strongly antigenic
than the female. Secondly, they noted that in women
with antibodies, the proportion of male births lessened as
parity increased implying that once sensitization takes place,
antibody or some related factor operates selectively in favor
o ft h ef e m a l ef e t u s[ 9]. Fetomaternal red cell alloimmuni-
zation, a condition that aﬀects one in a thousand pregnan-
cies, involves male predominance among D+ infants who
stimulate alloimmunizations in their D-mothers. The male
infants have lower hemoglobin and hematocrit values and
require more intrauterine, intravascular transfusions [10].
1.3. Fetal Microchimerism and Autoimmune Disease. About
80% of all people with autoimmune diseases are women.
Severalhypotheseshavebeenproposedtoexplainthereasons
for the gender diﬀerence such as hormones or stronger
immune responses in women. Progressive systemic sclerosis
(PSS), also known as scleroderma, is an autoimmune
disease that primarily aﬀects women in their postpartum
years and bears a striking resemblance to graft-versus-host
disease. Graft-versus-host disease often occurs after stem-
cell transplantation. Its clinical manifestation can cause
damage to the liver, gastrointestinal tract, skin, and mucosa
among other bodily systems. It also resembles a number
of spontaneously occurring autoimmune diseases including,
Sjogren’s syndrome, primary biliary cirrhosis, and system
lupus erythematous. Researchers have begun looking at
the association of microchimerism in certain autoimmune
diseases that primarily aﬀect women [11].
The ﬁrst study that investigated naturally acquired
microchimerism in autoimmune disease was a prospective,
blinded study of fetal microchimerism in women with PSS.
The study used a quantitative assay to test for male DNA
in women with PSS and healthy women who had given
birth to at least one son. Levels of DNA were signiﬁcantly
higher in women with PSS compared with healthy women.
Some women with PSS who had given birth to a male infant
decadesearlier had results equalto the highest quartile ofthe
assay used to test women currently pregnant with a healthy
male fetus [12]. Male DNA was found 1 to 27 years after
childbirth in six to eight women with PSS who had sons.
Likewise,womenwithPSSwhohadgivenbirthtoatleastone
son had larger amounts of male DNA than healthy women
and had extractable male DNA in skin lesions [13].
These ﬁndings ushered in a spate of studies suggesting
that because most autoimmune diseases occurred in women,
perhaps fetal cells played a role. Although many of these
studies have noted the presence of male fetal cells in women
with the disease, often times similar ﬁnding were found in
control groups. For example, a study of 22 women withISRN Nursing 3
systemic lupus erythematosus (SLE) and a healthy control
group found no diﬀerence in the amount or prevalence of
male fetal cells. Male microchimeric cells were found equally
in 50 percent of the women in the patient group and 50
percent in the control group. Disease activity did not appear
tocorrelatewithmicrochimerism. Yet,patientswithahistory
of lupus nephritis had a higher mean number of fetal cells
than patients with no such history [14].
Hashimoto’s thyroiditis is an autoimmune disease
believed to be the most common cause of primary hypothy-
roidism. It occurs primarily in women between the ages of
45 to 65 and has a range of symptoms including weight gain,
depression, fatigue, mania, memory loss, panic attacks, and
hair loss. Using thyroid gland specimens from 21 Hashimoto
thyroiditispatients,18patientswithmultinodulargoiter,and
17 women with normal thyroid glands (autopsy specimens),
investigators found Y chromosome DNA in 8 of the 21
women with Hashimoto’s disease, 1 in 18 women from the
multinodular group, and none of 17 healthy thyroid glands
[15].
Sjogren’s syndrome is an autoimmune disease character-
ized by dry mouth and dry eyes that can aﬀect other parts of
the body aswell. Itoccurs more frequently in woman over40
yearsofage.Fetalmicrochimerism was thefocusinastudyof
56 women with Sjogren’s syndrome, 42 of them had at least
one male child. Each subject had her peripheral blood, labial
salivary gland, and bronchoalveolar ﬂuids sampled. Male
DNA was shown to exist in 29% of salivary glands and 22%
of lung specimens in female patients with Sjogren’s. None
of these subjects had a history of blood transfusion. Male
chromosome PCR sequence was not detected in samples
from controls. Four of the subjects who were more than
60 years old had detectable fetal cells in their peripheral
blood up to 27 years postpartum [13]. One subject who
tested positive for male DNA did not have a male child or a
history ofabortion. She did,however, have a history ofblood
transfusion ﬁve years before the study. It is likely the male
DNA was derived from one or more transfusions in her past.
Examples of Autoimmune Diseases Where Fetal Y-Chromo-
somes Were Detected Decades after Pregnancy:
(i) progressive systemic sclerosis,
(ii) Hashimoto’s thyroiditis,
(iii) systemic lupus erythematosus,
(iv) Sjogren’s syndrome.
1.4. Microchimerism and Blood Transfusions. Microchimer-
ism from nonleukoreduced cellular blood products has been
found to persist from months to years after transfusion.
It was previously shown that in trauma patients given at
least two units of nonleukoreduced red blood cells, donor
leukocytes would decline markedly for the ﬁrst 3days after
transfusion only to increase tenfold on day 4 followed
by a secondary decline of donor cells from days 5 to 7
[16]. A subsequent study found that half of the trauma
patients who received leukoreduced blood transfusions had
detectable microchimeric cell populations for 2 to 3years
after transfusion [17]. Of the characteristics investigated that
might explain the persistent microchimerism, only the age of
the transfused unit was correlated.
Transfusion-related acute lung injury (TRALI) is the
most frequent cause of death from blood and blood-derived
products in the US [18]. It is widely accepted that the
transfusion-related reaction likely results from an antigen
antibody reactivity between the donor’s plasma and the
recipient’s blood cells or vice versa. The antibodies recognize
targets on the recipient’s white blood cells including HLA
Class I and II antigens. Pregnancies are thought to be
the major source of alloantibodies although prior donor
transfusions may also play a role.
In two cases presented by French physicians, TRALI
reactions occurred after transfusion of products from multi-
parousfemales.The recipientsdevelopedstrongalloantibod-
ies against HLA Class I and II antigens that were present on
the somatic cells of the donors’ husbands and shared by the
respective recipients. Typing the husbands proved useful in
identifying the speciﬁcity involved in the TRALI [19]. Just as
asex-mismatched HLA-identicalsolidorgan transplant from
male to female can end in rejection, a similar interaction
may be responsible for TRALI reactions with multiparous
donors who have been pregnant with sons and are, therefore,
microchimeric for H-Y antigen.
2.Discussion
The research into microchimerism, and more speciﬁcally
fetomaternal microchimerism, is still in its infancy. The lit-
erature has not progressed signiﬁcantly beyond a speculative
role for the long-term existence of fetal cells in women
with autoimmune diseases. The jury is still out as to the
relationship that fetomaternal microchimerism may play in
disease. Sincenearly allofthestudiesfoundasigniﬁcant level
of normal females with microchimerism, some researchers
have suggested that microchimeric cell populations that
occur as a result of pregnancy may have stem-cell-like
properties that can home in on damaged organs and tissues
and diﬀerentiateas part of the maternal repair response [20].
Just as cardiovascular diseases displaced infectious ill-
nesses with the introductionofpenicillin inthe 1950s,genet-
ically derived disorders are now among the most widespread
aﬄictions confronting contemporary society. As genetic
testing becomes an integral part of patient care, nurses will
be needed to provide education, counseling, and followup
services. Newgeneticdiscoverieswillspawn aneedtorethink
the nursing paradigm as it relates to education, practice, and
research [20]. As knowledge of microchimerism and other
genetically based illnesses expands, nurses will be confronted
with how to manage the new information and challenges it
will bring.
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